JP2018519324A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018519324A5 JP2018519324A5 JP2017568190A JP2017568190A JP2018519324A5 JP 2018519324 A5 JP2018519324 A5 JP 2018519324A5 JP 2017568190 A JP2017568190 A JP 2017568190A JP 2017568190 A JP2017568190 A JP 2017568190A JP 2018519324 A5 JP2018519324 A5 JP 2018519324A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- item
- composition
- enantiomer
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 41
- 239000003795 chemical substances by application Substances 0.000 claims description 27
- 206010028980 Neoplasm Diseases 0.000 claims description 23
- 201000011510 cancer Diseases 0.000 claims description 23
- 241000124008 Mammalia Species 0.000 claims description 18
- 150000001875 compounds Chemical class 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 15
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 13
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 13
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 13
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 13
- 206010009944 Colon cancer Diseases 0.000 claims description 12
- 241001465754 Metazoa Species 0.000 claims description 12
- 208000029742 colonic neoplasm Diseases 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 201000006402 rhabdoid cancer Diseases 0.000 claims description 12
- 206010005003 Bladder cancer Diseases 0.000 claims description 10
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 10
- 206010025323 Lymphomas Diseases 0.000 claims description 10
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 10
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 208000035475 disorder Diseases 0.000 claims description 10
- 201000005202 lung cancer Diseases 0.000 claims description 10
- 208000020816 lung neoplasm Diseases 0.000 claims description 10
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 10
- 201000002528 pancreatic cancer Diseases 0.000 claims description 10
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 10
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 10
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 6
- 206010014733 Endometrial cancer Diseases 0.000 claims description 6
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 6
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 6
- 208000034578 Multiple myelomas Diseases 0.000 claims description 6
- 206010029260 Neuroblastoma Diseases 0.000 claims description 6
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 6
- 206010033128 Ovarian cancer Diseases 0.000 claims description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 6
- 241000288906 Primates Species 0.000 claims description 6
- 206010060862 Prostate cancer Diseases 0.000 claims description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 6
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 6
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 6
- 208000008938 Rhabdoid tumor Diseases 0.000 claims description 6
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 6
- 208000006593 Urologic Neoplasms Diseases 0.000 claims description 6
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 6
- 201000010881 cervical cancer Diseases 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 6
- 201000004101 esophageal cancer Diseases 0.000 claims description 6
- 206010017758 gastric cancer Diseases 0.000 claims description 6
- 208000005017 glioblastoma Diseases 0.000 claims description 6
- 201000010536 head and neck cancer Diseases 0.000 claims description 6
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 6
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 6
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 6
- 208000032839 leukemia Diseases 0.000 claims description 6
- 201000001441 melanoma Diseases 0.000 claims description 6
- 201000002120 neuroendocrine carcinoma Diseases 0.000 claims description 6
- 206010038038 rectal cancer Diseases 0.000 claims description 6
- 201000001275 rectum cancer Diseases 0.000 claims description 6
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims description 6
- 201000011549 stomach cancer Diseases 0.000 claims description 6
- 229940125565 BMS-986016 Drugs 0.000 claims description 4
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 4
- FBKMWOJEPMPVTQ-UHFFFAOYSA-N N'-(3-bromo-4-fluorophenyl)-N-hydroxy-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole-3-carboximidamide Chemical compound NS(=O)(=O)NCCNC1=NON=C1C(=NO)NC1=CC=C(F)C(Br)=C1 FBKMWOJEPMPVTQ-UHFFFAOYSA-N 0.000 claims description 4
- YGACXVRLDHEXKY-WXRXAMBDSA-N O[C@H](C[C@H]1c2c(cccc2F)-c2cncn12)[C@H]1CC[C@H](O)CC1 Chemical compound O[C@H](C[C@H]1c2c(cccc2F)-c2cncn12)[C@H]1CC[C@H](O)CC1 YGACXVRLDHEXKY-WXRXAMBDSA-N 0.000 claims description 4
- 229950009791 durvalumab Drugs 0.000 claims description 4
- 229960005386 ipilimumab Drugs 0.000 claims description 4
- 229950007699 mogamulizumab Drugs 0.000 claims description 4
- 229960003301 nivolumab Drugs 0.000 claims description 4
- 229960002621 pembrolizumab Drugs 0.000 claims description 4
- 229940055760 yervoy Drugs 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 description 33
- 229940079593 drug Drugs 0.000 description 8
- 241000282412 Homo Species 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 0 CC(C)(c1nc(-c2cncc(C(C(F)(F)F)O)c2)cc(C)c11)N(c2c[n](CC(F)F)nc2)*1=O Chemical compound CC(C)(c1nc(-c2cncc(C(C(F)(F)F)O)c2)cc(C)c11)N(c2c[n](CC(F)F)nc2)*1=O 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562186157P | 2015-06-29 | 2015-06-29 | |
| US62/186,157 | 2015-06-29 | ||
| PCT/US2016/039885 WO2017004079A1 (en) | 2015-06-29 | 2016-06-28 | Lpt-723 and immune checkpoint inhibitor combinations and methods of treatment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020152003A Division JP7054547B2 (ja) | 2015-06-29 | 2020-09-10 | Ｌｐｔ－７２３と免疫チェックポイント阻害剤との組み合わせおよび処置の方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018519324A JP2018519324A (ja) | 2018-07-19 |
| JP2018519324A5 true JP2018519324A5 (OSRAM) | 2019-08-08 |
| JP6786529B2 JP6786529B2 (ja) | 2020-11-18 |
Family
ID=57609068
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017568190A Expired - Fee Related JP6786529B2 (ja) | 2015-06-29 | 2016-06-28 | Ｌｐｔ−７２３と免疫チェックポイント阻害剤との組み合わせおよび処置の方法 |
| JP2020152003A Expired - Fee Related JP7054547B2 (ja) | 2015-06-29 | 2020-09-10 | Ｌｐｔ－７２３と免疫チェックポイント阻害剤との組み合わせおよび処置の方法 |
| JP2022007869A Ceased JP2022058714A (ja) | 2015-06-29 | 2022-01-21 | Ｌｐｔ－７２３と免疫チェックポイント阻害剤との組み合わせおよび処置の方法 |
| JP2023103633A Pending JP2023120391A (ja) | 2015-06-29 | 2023-06-23 | Ｌｐｔ－７２３と免疫チェックポイント阻害剤との組み合わせおよび処置の方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020152003A Expired - Fee Related JP7054547B2 (ja) | 2015-06-29 | 2020-09-10 | Ｌｐｔ－７２３と免疫チェックポイント阻害剤との組み合わせおよび処置の方法 |
| JP2022007869A Ceased JP2022058714A (ja) | 2015-06-29 | 2022-01-21 | Ｌｐｔ－７２３と免疫チェックポイント阻害剤との組み合わせおよび処置の方法 |
| JP2023103633A Pending JP2023120391A (ja) | 2015-06-29 | 2023-06-23 | Ｌｐｔ－７２３と免疫チェックポイント阻害剤との組み合わせおよび処置の方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (4) | US9861621B2 (OSRAM) |
| EP (1) | EP3313186A4 (OSRAM) |
| JP (4) | JP6786529B2 (OSRAM) |
| HK (1) | HK1254954A1 (OSRAM) |
| WO (1) | WO2017004079A1 (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201322725D0 (en) | 2013-12-20 | 2014-02-05 | Immodulon Therapeutics Ltd | Cancer therapy |
| WO2017004079A1 (en) * | 2015-06-29 | 2017-01-05 | Biomed Valley Discoveries, Inc. | Lpt-723 and immune checkpoint inhibitor combinations and methods of treatment |
| IL322943A (en) | 2017-07-11 | 2025-10-01 | Compass Therapeutics Llc | Agonist antibodies that bind human CD137 and their use |
| US11718679B2 (en) | 2017-10-31 | 2023-08-08 | Compass Therapeutics Llc | CD137 antibodies and PD-1 antagonists and uses thereof |
| EP3713961A2 (en) | 2017-11-20 | 2020-09-30 | Compass Therapeutics LLC | Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof |
| TW201938168A (zh) * | 2018-01-10 | 2019-10-01 | 韓商保寧製藥股份公司 | 預防或治療癌症之包含pi3激酶抑制劑與免疫檢查點抑制劑的醫藥組成物 |
| CA3104218A1 (en) * | 2018-06-25 | 2020-01-02 | Immodulon Therapeutics Limited | Cancer therapy |
| US11046769B2 (en) | 2018-11-13 | 2021-06-29 | Compass Therapeutics Llc | Multispecific binding constructs against checkpoint molecules and uses thereof |
| US20240009252A1 (en) * | 2020-08-18 | 2024-01-11 | Curators Of The University Of Missouri | Compositions and methods of treatment comprising tumor-targeting bacteria and chemotherapy or immunotherapy agent |
| WO2023091747A1 (en) * | 2021-11-22 | 2023-05-25 | Axial Therapeutics, Inc. | Modulator compounds, pharmaceutical compositions and uses thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5235033A (en) | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| ATE102631T1 (de) | 1988-11-11 | 1994-03-15 | Medical Res Council | Klonierung von immunglobulin sequenzen aus den variabelen domaenen. |
| US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
| DE60045706D1 (de) | 1999-03-18 | 2011-04-21 | Exiqon As | Detektion von genmutationen mittels lna primer |
| CA2522637C (en) | 2003-04-17 | 2014-01-21 | Alnylam Pharmaceuticals, Inc. | Modified irna agents |
| US20050182005A1 (en) | 2004-02-13 | 2005-08-18 | Tuschl Thomas H. | Anti-microRNA oligonucleotide molecules |
| WO2005116250A2 (en) | 2004-05-26 | 2005-12-08 | Rosetta Genomics Ltd. | Viral and viral associated mirnas and uses thereof |
| WO2006126040A1 (en) | 2005-05-25 | 2006-11-30 | Rosetta Genomics Ltd. | Bacterial and bacterial associated mirnas and uses thereof |
| KR102702287B1 (ko) * | 2012-05-15 | 2024-09-04 | 브리스톨-마이어스 스큅 컴퍼니 | Pd-1/pd-l1 신호전달을 방해하는 것에 의한 암 면역요법 |
| CA2925601C (en) * | 2013-09-25 | 2022-11-01 | Vertex Pharmaceuticals Incorporated | A selective inhibitor of phosphatidylinositol 3-kinase-gamma |
| CA2944903A1 (en) * | 2014-04-24 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response |
| US10881732B2 (en) * | 2015-06-01 | 2021-01-05 | Maine Medical Center Research Institute | Enhancing the therapeutic activity of an immune checkpoint inhibitor |
| WO2017004079A1 (en) * | 2015-06-29 | 2017-01-05 | Biomed Valley Discoveries, Inc. | Lpt-723 and immune checkpoint inhibitor combinations and methods of treatment |
| SMT202100131T1 (it) * | 2015-07-14 | 2021-05-07 | Bristol Myers Squibb Co | Metodo di trattamento di un cancro usando un inibitore di checkpoint immunitari; anticorpo che si lega al recettore della morte programmata-1 (pd-1) o al ligando della morte programmata 1 (pd-l1) |
| JO3620B1 (ar) * | 2015-08-05 | 2020-08-27 | Amgen Res Munich Gmbh | مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم |
| US20170129911A1 (en) * | 2015-11-10 | 2017-05-11 | Massachusetts Institute Of Technology | Complexes comprising a platinum compound and an immune checkpoint inhibitor and related methods |
-
2016
- 2016-06-28 WO PCT/US2016/039885 patent/WO2017004079A1/en not_active Ceased
- 2016-06-28 EP EP16818616.1A patent/EP3313186A4/en not_active Withdrawn
- 2016-06-28 JP JP2017568190A patent/JP6786529B2/ja not_active Expired - Fee Related
- 2016-06-28 HK HK18114058.0A patent/HK1254954A1/zh unknown
- 2016-06-28 US US15/195,723 patent/US9861621B2/en active Active
-
2017
- 2017-11-10 US US15/809,759 patent/US10485796B2/en active Active
-
2019
- 2019-11-22 US US16/692,560 patent/US10716782B2/en not_active Expired - Fee Related
-
2020
- 2020-06-29 US US16/915,562 patent/US11033537B2/en not_active Expired - Fee Related
- 2020-09-10 JP JP2020152003A patent/JP7054547B2/ja not_active Expired - Fee Related
-
2022
- 2022-01-21 JP JP2022007869A patent/JP2022058714A/ja not_active Ceased
-
2023
- 2023-06-23 JP JP2023103633A patent/JP2023120391A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018519324A5 (OSRAM) | ||
| US10220038B2 (en) | Pharmaceutical combinations | |
| US20230202981A1 (en) | Novel small molecules for targeted degradation of untargetable kras in cancer therapy | |
| CL2018001371A1 (es) | Uso de un inhibidor de b-raf y de un inhibidor de mek 1/2 para el tratamiento de un paciente que padece melanoma (divisional solicitud 201502807) | |
| JP2019506403A5 (OSRAM) | ||
| CA3057969A1 (en) | Combination therapy | |
| JP2017530984A5 (OSRAM) | ||
| KR20170058432A (ko) | 상승 효과적 아우리스타틴 조합 | |
| JP2017529382A5 (OSRAM) | ||
| JP2017500320A5 (OSRAM) | ||
| JP2017510579A5 (OSRAM) | ||
| JP2017160178A5 (OSRAM) | ||
| US12116363B2 (en) | Combinations for immune-modulation in cancer treatment | |
| JP2014511383A5 (OSRAM) | ||
| JP2017502016A5 (OSRAM) | ||
| JP2020523354A5 (OSRAM) | ||
| JP2019530706A5 (OSRAM) | ||
| RU2018128796A (ru) | Противоопухолевое средство, содержащее иммуномодулятор и усилитель противоопухолевого эффекта | |
| WO2022007745A1 (zh) | 西奥罗尼及其联合用药治疗非霍奇金淋巴瘤的用途 | |
| JP2018511642A5 (OSRAM) | ||
| Ujjani et al. | Phase I study of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma (Alliance 051103) | |
| Anandappa et al. | Emerging novel therapeutic agents in the treatment of patients with gastroesophageal and gastric adenocarcinoma | |
| JP2017530132A5 (OSRAM) | ||
| RU2020126340A (ru) | Способы и комбинированное терапевтическое средство для лечения рака | |
| Keystone et al. | THU0228 Tofacitinib, an oral Janus kinase inhibitor: post-hoc analyses of efficacy and safety of monotherapy versus combination therapy in a phase 3 rheumatoid arthritis population |